Michael Krainer
Overview
Explore the profile of Michael Krainer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welsch E, Bonstingl L, Holzer B, Schuster E, Weiss E, Zaharie A, et al.
Clin Exp Metastasis
. 2024 Sep;
41(6):937-945.
PMID: 39305397
Circulating tumor cells (CTCs) are an established prognostic marker in metastatic prostate cancer (PrC) but have received little attention in localized high-risk disease. Peripheral blood was obtained from patients with...
2.
Welsch E, Schuster E, Krainer M, Marhold M, Bartsch R, Fischer M, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831613
Liquid biopsy is a promising tool for therapy monitoring of cancer patients, but a need for further research in this field exists in order to improve sensitivity, specificity, standardization and...
3.
Steinbach C, Merchant A, Zaharie A, Horak P, Marhold M, Krainer M
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428811
Recently, the development of immunotherapies such as cellular therapy, monoclonal antibodies, vaccines and immunomodulators has revolutionized the treatment of various cancer entities. In order to close the existing gaps in...
4.
Sajdik C, Schuster E, Holzer B, Krainer M, Deutschmann C, Peter S, et al.
Breast Cancer Res Treat
. 2022 Sep;
196(1):75-85.
PMID: 36074219
Purpose: Circulating tumor cells (CTCs) hold promise to be a non-invasive measurable biomarker in all cancer stages. Because the analysis of CTCs is still a technical challenge, we compared different...
5.
Marhold M, Udovica S, Topakian T, Horak P, Horvat R, Tomasich E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159020
Targeting testosterone signaling through androgen deprivation therapy (ADT) or antiandrogen treatment is the standard of care for advanced prostate cancer (PCa). Although the large majority of patients initially respond to...
6.
Marhold M, Kramer G, Krainer M, Le Magnen C
Cancer Lett
. 2021 Dec;
526:304-310.
PMID: 34863887
Prostate cancer (PCa) is the most common non-cutaneous cancer in men in Europe and is predicted to exhibit declining mortality in the European Union (EU) due to various recent improvements...
7.
Marhold M, Heinzel A, Merchant A, Perco P, Krainer M
J Vis Exp
. 2021 Jun;
(171).
PMID: 34125094
A synthetic lethal interaction between two genes is given when knock-out of either one of the two genes does not affect cell viability but knock-out of both synthetic lethal interactors...
8.
Tomasich E, Topakian T, Heller G, Udovica S, Krainer M, Marhold M
Transl Res
. 2020 Nov;
230:21-33.
PMID: 33197651
Loss of hepatocellular carcinoma-related protein 1 (HCRP1) (alias VPS37A) plays a role in endocytosis of receptor tyrosine kinases as a member of the ESCRT complex and has been linked to...
9.
Marhold M, Topakian T, Agis H, Bartsch R, Berghoff A, Brodowicz T, et al.
ESMO Open
. 2020 Oct;
5(5):e000880.
PMID: 33051192
Background: Novel treatment modalities like targeted therapy and immunotherapy are currently changing treatment strategies and protocols in the field of medical oncology. Methods: Numbers of patients and patient contacts admitted...
10.
Reiser E, Potsch N, Seebacher V, Reinthaller A, Wimazal F, Fleischmann E, et al.
Arch Gynecol Obstet
. 2020 Oct;
303(2):557-563.
PMID: 33009994
Purpose: To assess the impact of frailty on compliance of standard therapy, complication, rate and survival in patients with gynecological malignancy aged 80 years and older. Methods: In total, 83...